Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multisite, Randomized, Open-label Phase III Clinical Trial (CLOVER Study)Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

NCT03926091 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT03926091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03926091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multisite, Randomized, Open-label Phase III Clinical Trial (CLOVER Study)Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Unknown status
Start date
April 1, 2019
Completion date
November 1, 2025
Enrollment
2,172 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer